Mitochondrial metabolism in cancer stem cells: a therapeutic target for colon cancer

It has been proposed that the selective elimination of cancer stem cells (CSCs) using targeted therapy could greatly reduce tumor growth, recurrence, and metastasis. To develop effective therapeutic targets for CSC elimination, we aimed to define the properties of CSC mitochondria, and identify CSC-...

Full description

Saved in:
Bibliographic Details
Published in:BMB reports 2015, 48(10), , pp.539-540
Main Authors: Song, I.S., Inje University, Busan, Republic of Korea, Jeong, Y.J., Inje University, Busan, Republic of Korea, Han, J., Inje University, Busan, Republic of Korea
Format: Article
Language:English
Subjects:
Colon cancer,Cancer stem cells,Peroxiredoxin 3,CD133,FOXM1
NEOPLASMAS
NEOPLASME
NEOPLASMS
화학
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been proposed that the selective elimination of cancer stem cells (CSCs) using targeted therapy could greatly reduce tumor growth, recurrence, and metastasis. To develop effective therapeutic targets for CSC elimination, we aimed to define the properties of CSC mitochondria, and identify CSC-mitochondria- specific targets in colon cancer. We found that colon CSCs utilize mitochondrial oxidative phosphorylation (OXPHOS) to produce ATP. We also found that forkhead box protein 1 (FOXM1)-induced peroxiredoxin 3 (PRDX3) maintains the mitochondrial function, and the FOXM1/PRDX3 mitochondrial pathway maintains survival of colon CSCs. Furthermore, FOXM1 induces CD133 (PROM1/prominin 1) expression, which maintains the stemness of colon CSCs. Together, our findings indicate that FOXM1, PRDX3, and CD133 are potential therapeutic targets for the elimination of CSCs in colon cancer.
ISSN:1976-6696
1976-670X
DOI:10.5483/bmbrep.2015.48.10.179